Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Lowered to $3.00 at B. Riley
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective reduced by B. Riley from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at […]
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its price objective reduced by B. Riley from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at […]
